Table 3. Two-year overall survival of patients according to their PD-1, PD-L1, and PD-L2 expression status.
| Clinical features, n | Entire cohort | Two-year overall survival (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (n = 76) | PD-1 | P | PD-L1 | P | PD-L2 | P | ||||
| Low (n= 70) | High (n= 6) | Low (n = 66) | High (n = 10) | Low (n = 44) | High (n = 32) | |||||
| Age | ||||||||||
| ≤60 | 46 | 88.7 | 50.0 | 0.028 | 84.5 | 85.7 | 0.764 | 88.6 | 76.0 | 0.405 |
| >60 | 30 | 66.2 | 0.0 | 0.134 | 61.9 | 0.0 | 0.737 | 66.3 | 28.6 | 0.409 |
| Gender | ||||||||||
| Male | 37 | 88.0 | 33.3 | 0.008 | 78.2 | 100.0 | 0.274 | 83.3 | 82.4 | 0.718 |
| Female | 39 | 74.0 | 33.3 | 0.231 | 73.9 | 33.3 | 0.344 | 81.5 | 36.0 | 0.111 |
| ECOG PS | ||||||||||
| <2 | 41 | 91.6 | 40.0 | 0.004 | 82.0 | 100.0 | 0.377 | 92.4 | 66.1 | 0.070 |
| ≥2 | 35 | 65.9 | 0.0 | 0.199 | 66.2 | 50.0 | 0.981 | 57.9 | 65.9 | 0.572 |
| Serum LDH | ||||||||||
| Not elevated | 42 | 71.6 | 40.0 | 0.162 | 66.9 | 66.7 | 0.754 | 75.2 | 50.6 | 0.243 |
| Elevated | 34 | 89.9 | 0.0 | 0.024 | 87.5 | 80.0 | 0.949 | 87.7 | 83.6 | 0.813 |
| Serum EBV DNA load | ||||||||||
| Not detected | 60 | 81.7 | 50.0 | 0.143 | 80.4 | 71.4 | 0.086 | 85.4 | 67.4 | 0.248 |
| Detected | 16 | 77.4 | 0.0 | 0.108 | 58.0 | 100.0 | 0.354 | 64.6 | 60.0 | 0.756 |
| Tumor location | ||||||||||
| Non-deep lesion | 25 | 77.6 | 50.0 | 0.469 | 70.6 | 100.0 | 0.338 | 77.4 | 71.4 | 0.530 |
| Deep lesion | 51 | 81.4 | 0.0 | 0.009 | 77.9 | 62.5 | 0.730 | 83.1 | 65.5 | 0.368 |
| CSF protein | ||||||||||
| Not elevated | 36 | 91.8 | 33.3 | 0.001 | 83.5 | 100.0 | 0.320 | 83.3 | 90.9 | 0.569 |
| Elevated | 30 | 64.3 | 50.0 | 0.673 | 72.3 | 33.3 | 0.440 | 76.6 | 30.3 | 0.249 |
| Not available | 10 | 85.7 | 0.0 | 0.155 | 68.6 | 100.0 | 0.558 | 0.0 | 60.0 | 0.295 |
| IELSG | ||||||||||
| Low (0-1) | 12 | 77.1 | 50.0 | 0.426 | 65.6 | 100.0 | 0.377 | 75.0 | 66.7 | 0.743 |
| Intermediate (2-3) | 46 | 88.9 | 33.3 | 0.015 | 82.4 | 100.0 | 0.315 | 83.2 | 85.7 | 0.898 |
| High (4-5) | 8 | 28.1 | N/A | N/A | 66.7 | 0.0 | 0.623 | 50.0 | 31.3 | 0.275 |
| Missing | 10 | 85.7 | 0.0 | 0.155 | 100.0 | 68.6 | 0.558 | 100.0 | 60.0 | 0.295 |
| MSKCC | ||||||||||
| Low (1) | 15 | 100.0 | 0.0 | <0.001 | 84.6 | 100.0 | 0.571 | 100.0 | 66.7 | 0.070 |
| Intermediate (2) | 32 | 83.9 | 66.7 | 0.531 | 77.6 | 100.0 | 0.321 | 81.5 | 80.0 | 0.858 |
| High (3) | 29 | 62.1 | 0.0 | 0.333 | 67.2 | 0.0 | 0.235 | 65.2 | 33.7 | 0.468 |
| Initial interim response | ||||||||||
| CR1 | 39 | 83.6 | 25.0 | 0.007 | 77.6 | 66.7 | 0.839 | 80.8 | 65.6 | 0.605 |
| Non-CR1 | 37 | 77.0 | 50.0 | 0.474 | 73.8 | 75.0 | 0.896 | 80.9 | 64.5 | 0.282 |
| Upfront ASCT | ||||||||||
| Yes | 16 | 100.0 | 0.0 | <0.001 | 92.3 | 100.0 | 0.395 | 100.0 | 85.7 | 0.738 |
| No | 60 | 74.4 | 40.0 | 0.160 | 53.3 | 71.8 | 0.780 | 76.2 | 54.5 | 0.307 |
| Consolidation WBRT | ||||||||||
| Yes | 12 | 66.7 | 50.0 | 0.707 | 70.4 | 0.0 | 0.089 | 79.1 | 0.0 | 0.021 |
| No | 64 | 85.4 | 0.0 | <0.001 | 78.0 | 100.0 | 0.159 | 81.9 | 80.9 | 0.962 |
ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; EBV, Epstein-Barr virus; CSF, cerebrospinal fluid; IELSG, International Extranodal Lymphoma Study Group; MSKCC, Memorial Sloan Kettering Cancer Center; CR1, complete response after first two cycles of chemotherapy; ASCT, autologous stem-cell transplantation; WBRT, whole-brain radiotherapy; N/A, not available.